Location History:
- East Palo Alto, CA (US) (1994)
- Redwood Shores, CA (US) (1994 - 1995)
- Palo Alto, CA (US) (1987 - 2000)
- East Haven, CT (US) (2000)
- San Mateo, CA (US) (1998 - 2001)
- Woodbridge, CT (US) (2001)
Company Filing History:
11 out of 88 
2 out of 281 
1 out of 1,168 
Years Active: 1987-2001
Title: David A Campbell: Innovative Mind in Metalloprotease Research
Introduction:
David A Campbell, a prominent inventor and researcher based in San Mateo, CA, has made significant contributions to the field of metalloprotease inhibitors. With 17 patents to his name, Campbell has demonstrated a deep understanding of the potential applications of these compounds in treating various disease states and conditions. This article delves into Campbell's latest patents, career highlights, collaborations, and his invaluable contributions to the field of pharmaceutical sciences.
Latest Patents:
Campbell's recent patents showcase his expertise in developing inhibitors of metalloproteases, specifically matrix metalloproteases, collagenase-1, and stromelysin-1. These compounds, consisting of mercaptoketone and mercaptoalcohol compounds, exhibit considerable potential in pharmaceutical compositions for addressing tissue breakdown and promoting wound healing.
The disclosed inhibitors of matrix metalloproteases offer promising therapeutic opportunities for treating arthropathy, dermatological conditions, bone resorption, inflammatory diseases, and tumor invasion. Similarly, the inhibitors of collagenase-1 and stromelysin-1 hold great potential in the management of rheumatoid arthritis and other tissue breakdown-related conditions.
Career Highlights:
Throughout his career, David A Campbell has worked with notable companies such as Affymax Technologies and Glaxo Wellcome Inc. (now known as GlaxoSmithKline). These organizations provided him with an ideal platform to further his research on metalloprotease inhibitors and their applications in treating various diseases.
Collaborations:
Campbell has collaborated with esteemed colleagues to explore the multifaceted aspects of metalloprotease inhibitors. Notably, he has worked alongside Dinesh Vinoobhai Patel and Anna Katrin Szardenings, both accomplished researchers and industry experts who have made significant contributions to the field.
Conclusion:
David A Campbell's contributions to the field of metalloprotease inhibitors are substantial, and his patented inventions hold great promise for the treatment of various disease states involving tissue breakdown. His collaborations with distinguished researchers further amplify the impact of his work, fostering innovation and advancements in this critical area of pharmaceutical sciences.
As a leading figure in the field, Campbell's dedication and expertise continue to drive the development of new and improved therapies for patients suffering from arthropathy, dermatological conditions, bone resorption, inflammatory diseases, tumor invasion, and rheumatoid arthritis. He serves as a shining example of an innovative mind shaping the future of pharmaceutical research and development.